VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS
DGAP-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS Vancouver, BC, Canada, November 3rd, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on the development of next generation cancer therapeutics and infectious disease vaccines is pleased to announce the successful completion of its protein-based COVID vaccine (AccuVAC-PT001) toxicology studies in non-rodent rabbit model. The AccuVAC-PT001 vaccine is an injectable vaccine capable of inducing a powerful and sustainable antibody response in both rodent and non-rodent models. The vaccine proprietary recipe consists of chemically modifying the COVID Spike protein with the AccumTM moiety. Once delivered in animals, the protein accumulates very efficiently in target antigen presenting cells leading to extremely high antibody titers. Extensive analyses conducted on vaccinated rabbits showed no effects induced by the vaccine on animal behaviour, food intake, body weight, skin at injected sites and liver enzymatic function amongst other investigated organs. Defence is currently working on two different protein-based vaccine candidates. Defence Therapeutics is currently working on developing both a vaccine to block COVID infection and pathophysiology as well as an intranasally-delivered vaccine designed to completely block viral transmission. The developed "know-how" combined to the versatility of the AccumTM technology position Defence as a leading biotech company with its AccumTM platform to rapidly face current and future possible pandemics based on both injectable and non-invasive vaccine formulations. Dr. Moutih Rafei, Defence's VP Research and Development, has reviewed and approved the scientific disclosure contained in this press release. Dr. Rafei has a PhD in Experimental Medicine from McGill University and received his post-doctoral training at Université de Montréal. He is an immuno-oncologist who specializes in the fields of T-cell development, stem cell biology, cancer immunotherapy and autoimmune diseases. For further information:
03.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Defence Therapeutics Inc. |
1680 - 200 Burrard St | |
V6C3L6 Vancouver | |
Canada | |
E-mail: | info@defencetherapeutics.com |
Internet: | https://defencetherapeutics.com |
ISIN: | CA24463V1013 |
WKN: | A3CN14 |
Listed: | Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto |
EQS News ID: | 1245571 |
End of News | DGAP News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: